Loading stock data…
$1.45-0.02 (-1.36%)
Innate Pharma S.A.
Innate Pharma S.A. in the Healthcare sector is trading at $1.45 with a market capitalization of $164M. Wall Street consensus targets $6.67 (3 analysts), implying a +359.8% move over the next 12 months. The stock is currently near its 52-week low of $1.17, remaining 16.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials...